Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 10/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.77 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.77 |
| ▸ | PGR | P06401 | 2/20 | 0.77 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.77 |
| ▸ | SHBG | P04278 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | AR | P10275 | 1/20 | 0.76 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1685787 | 1.00 | HIF1A (0.81) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL12045184 | 1.00 | HIF1A (0.81) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL1685788 | 1.00 | HIF1A (0.81) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL22872809 | 1.00 | HIF1A (0.81) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL21231472 | 0.92 | HIF1A (0.78) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL21340506 | 0.90 | HIF1A (0.75) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL1685722 | 0.90 | HIF1A (0.77) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL25854534 | 0.90 | HIF1A (0.77) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL1685723 | 0.90 | HIF1A (0.77) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL14523057 | 0.90 | HIF1A (1.00) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2026818-B1 | COMBINATION OF STEROIDS HAVING TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY | BODOR NICHOLAS S (US) | 2010-12-22 | — | — | EP | disclosed |
| US-7691811-B2 | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye | BODOR LABORATORIES, INC. | 2010-04-06 | — | — | US | disclosed |
| US-7691811-B2 | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye | BODOR LABORATORIES, INC. | 2010-04-06 | — | — | US | disclosed |
| US-7687484-B2 | Enhancing the activity and/or duration of action of soft anti-inflammatory steroids such as loteprednol etabonate with a synergistic amount of another steroid such as cortisone | BODOR LABORATORIES, INC. | 2010-03-30 | — | — | US | disclosed |
| US-7687484-B2 | Enhancing the activity and/or duration of action of soft anti-inflammatory steroids such as loteprednol etabonate with a synergistic amount of another steroid such as cortisone | BODOR LABORATORIES, INC. | 2010-03-30 | — | — | US | disclosed |
| US-20080194468-A1 | TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY AND METHODS AND COMPOSITIONS FOR TREATING DRY EYE | BODOR LABORATORIES, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194468-A1 | TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY AND METHODS AND COMPOSITIONS FOR TREATING DRY EYE | BODOR LABORATORIES, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080004246-A1 | Transporter enhanced corticosteroid activity | BODOR LABORATORIES, INC. | 2008-01-03 | — | — | US | disclosed |
| US-20080004246-A1 | Transporter enhanced corticosteroid activity | BODOR LABORATORIES, INC. | 2008-01-03 | — | — | US | disclosed |
| WO-2007142842-A2 | COMBINATION OF ANTI-INFLAMMATORY STEROIDS HAVING TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY | BODOR NICHOLAS S (US) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194468-A1 | TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY AND METHODS AND COMPOSITIONS FOR TREATING DRY EYE | HSD3B1, HSD3B2, HSD11B1 | HIF1A 1047/4885LMNA 3899/4885NR3C1 37/4885 |
| US-20080004246-A1 | Transporter enhanced corticosteroid activity | HSD3B1, HSD11B1, EBP | HIF1A 1372/4885LMNA 3563/4885NR3C1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.